hackint0sh/New-Dataset huggingface dataset:
Results: Ninety newborns were randomized into three groups (30 in each group). A statistically significant difference was determined between the median values of total crying time according to groups (p\<0.001). A statistically significant difference was determined between the median values of pulse measurements according to the interaction of group and time (p\<0.001). A statistically significant difference was determined between the median values of saturation measurements according to groups (p=0.001). A statistically significant difference was determined between the mean values of cortisol and GRP78 measurements according to the group and time interaction (p\<0.001).
Conclusion: It was concluded that white noise and kangaroo care help reduce newborns' stress in the case of heel lancing. conditions: Healthy Newborns studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is parallel-group, randomized controlled. primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE maskingDescription: Due to the nature of the intervention, blinding could not be done for the participants, and the two researchers who collected the data, but the statistician and two other researchers who analyzed the results were unaware of group allocation. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 90 type: ACTUAL name: Kangaroo care and White noise measure: Ninety newborns were randomized into three groups (30 in each group). sex: ALL minimumAge: 32 Hours maximumAge: 72 Hours stdAges: CHILD facility: Bayburt University city: Bayburt zip: 69100 country: Turkey lat: 40.25631 lon: 40.22289 hasResults: False
nctId: NCT06278428 id: DEE UMC briefTitle: Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age overallStatus: RECRUITING date: 2023-11-01 date: 2028-11-01 date: 2028-11-01 date: 2024-02-26 date: 2024-02-28 name: Number 2 Children's Hospital, Ho Chi Minh City class: OTHER briefSummary: According to estimates by the World Health Organization in 2019, more than 50 million people around the world have epilepsy. Nearly 80% of patients with epilepsy live in developing countries. Among them, children under 2 years old are the group with the highest incidence of epilepsy, and at the same time, the most dangerous epilepsy groups are also likely to start at these ages. World medical literature on epileptic encephalopathy and early-onset development before 2 years of age records that 71% of children have severe intellectual disability and 60% of children show signs of autism spectrum disorder, of which Children with epileptic and developmental encephalopathy due to genetic causes are at higher risk of developing neurodevelopmental disorders than children with epileptic and developmental encephalopathy due to other causes. However, in Vietnam, there is no research on this topic.
The question is what are the phenotypes, genotypes, and progression after 2 years of follow-up of Vietnamese children with epileptic and developmental encephalopathy with onset before 2 years of age? conditions: Epilepsy; Seizure conditions: Child Development conditions: Gene Abnormality conditions: Early Onset Disorder studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED measure: Genotye of early-onset developmental epileptic encephalopathy measure: Phenotye of early-onset developmental epileptic encephalopathy measure: Progression of epileptic encephalopathy and early onset developmental epileptic encephalopathy sex: ALL maximumAge: 23 Months stdAges: CHILD facility: Children hospital number 2 status: RECRUITING city: Ho Chi Minh zip: 700000 country: Vietnam name: Thuy-Minh-Thu LT NGUYEN, MD role: CONTACT phone: +84983966371 email: dr.thu.nguyen.neurology@gmail.com lat: 10.82302 lon: 106.62965 hasResults: False
nctId: NCT06278402 id: JinnahH briefTitle: Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. overallStatus: COMPLETED date: 2023-07-01 date: 2024-01-06 date: 2024-01-16 date: 2024-02-26 date: 2024-02-26 name: Jinnah Hospital class: OTHER briefSummary: To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan. Efficacy of treatment in patients presenting with alopecia areata will be assessed using SALT Score on follow up at 6,12 and 24 weeks where four categories of treatment response were defined: 0 (re-growth ≤10%), 1 (11-25%), 2 (26-50%), 3 (51-75%) and 4 (re-growth \>75%). Efficacy will be considered if re-growth ≥ 2. conditions: Alopecia Areata conditions: Alopecia Totalis conditions: Alopecia Universalis studyType: INTERVENTIONAL phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This study includes patients with moderate to severe Alopecia Areata, totalis and universalis. The efficacy of JAK 1/3 inhibitor, Tofacitinib will be assessed by using SALT score (Severity of Alopecia Tool) at Baseline, 06 weeks, 12 weeks and 24 weeks. Oral Tofacitinib given at a dose of 5 mg twice daily after relevant investigations. The data will be analyzed in SPSS version 23. primaryPurpose: TREATMENT masking: NONE count: 30 type: ACTUAL name: Tofacitinib measure: Alopecia sex: ALL minimumAge: 15 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT facility: Misbah Zari Qadir city: Karachi state: Sindh country: Pakistan lat: 24.8608 lon: 67.0104 hasResults: False
nctId: NCT06278389 id: ADYY-ACC017-101 id: CTR20240167 type: REGISTRY domain: chinadrugtrials.org.cn briefTitle: Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants overallStatus: RECRUITING date: 2024-01-24 date: 2024-04-23 date: 2024-04-23 date: 2024-02-26 date: 2024-03-05 name: Jiangsu Aidea Pharmaceutical Co., Ltd class: INDUSTRY name: Chengdu Aidea Pharmaceutical Technology Co., Ltd briefSummary: The objective of this clinical trial is to investigate the safety and tolerability of single ascending dose ACC017 tablets in Chinese healthy adult participants. This study aims to address the following major questions:
* Drug-drug interactions (DDIs) when ACC017 tablets are co-administered with emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) tablets (II). conditions: Healthy Adult Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 52 type: ESTIMATED name: ACC017 tablets name: Emtricitabine and Tenofovir Alafenamide Fumarate Tablets measure: Frequency, causality, severity, and expectedness of adverse events (AEs) measure: ACC017 PK parameter: Cmax (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: C24h (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: AUC0-t (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: AUC0-∞ (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: Tmax (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: t1/2 (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: Vz/F (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: CL/F (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: λz (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: AUC_%Extrap (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: MRT0-t (after a single mono-drug administration under the fasting condition) measure: ACC017 PK parameter: MRT0-∞ (after a single mono-drug administration under the fasting condition) measure: Vital signs: temperature measure: Vital sign: pulse measure: Vital signs: blood pressure measure: Vital signs: respiration measure: Electrocardiogram (ECG): heart rate measure: Electrocardiogram (ECG): PR interval measure: Electrocardiogram (ECG): QRS duration measure: Electrocardiogram (ECG): QTc interval measure: ACC017 PK parameter: Cmax measure: ACC017 PK parameter: C24h measure: ACC017 PK parameter: AUC0-t measure: ACC017 PK parameter: AUC0-∞ measure: ACC017 PK parameter: Tmax measure: ACC017 PK parameter: t1/2 measure: ACC017 PK parameter: Vz/F measure: ACC017 PK parameter: CL/F measure: ACC017 PK parameter: λz measure: ACC017 PK parameter: AUC_%Extrap measure: ACC017 PK parameter: MRT0-t measure: ACC017 PK parameter: MRT0-∞ sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Beijing Ditan Hospital Capital Medical University status: RECRUITING city: Beijing zip: 100015 country: China name: Fujie Zhang role: CONTACT email: treatment@chinaaids.cn name: Chaoying Hu role: CONTACT email: hucarol@126.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06278376 id: f/2023/045 briefTitle: Evaluation of Diagnoses and Clinical Outcomes in Children Undergoing MRI Scans overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-25 date: 2024-12-31 date: 2024-12-31 date: 2024-02-26 date: 2024-02-26 name: Jessa Hospital class: OTHER briefSummary: The aim of this study is to evaluate the indications and therapeutical consequences of MRI scans of (young) children undergoing risky remote anaesthesia. The investigators want to aim for a clear indication in children undergoing MRI in the future before undergoing possible unnecessary procedures and MRI scans. conditions: Magnetic Resonance Imaging studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 410 type: ACTUAL measure: Incidence measure: Therapeutical implications: diagnosis measure: Therapeutical implications: treatment measure: Clinical indications measure: Evaluation of body part measure: Evaluation of symptoms measure: Clinical outcome: adverse event measure: Clinical outcome: surgery measure: Clinical outcome: admission to hospital measure: Clinical outcome: mortality measure: Evaluation of age measure: Influence of COVID-19 pandemic sex: ALL minimumAge: 6 Months maximumAge: 16 Years stdAges: CHILD facility: Jessa hospital city: Hasselt zip: 3500 country: Belgium lat: 50.93106 lon: 5.33781 hasResults: False
nctId: NCT06278363 id: StrokeSex_23 briefTitle: Sexual Nursing Care in Stroke Patients acronym: StrokeSex_23 overallStatus: RECRUITING date: 2023-11-01 date: 2024-06-30 date: 2025-04-30 date: 2024-02-26 date: 2024-03-28 name: IRCCS Centro Neurolesi "Bonino-Pulejo" class: OTHER briefSummary: The study aims to assess the impact of "sexual nursing care" on sexual dysfunctions in Italian stroke patients.
In conclusion, the importance of sexual health in stroke patients is highlighted as an indicator of quality of life. Targeted nursing interventions can facilitate timely diagnosis and a personalized approach to patients and partners. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: We aim to assess the effectiveness of an intervention in stroke subjects to increase awareness of sexual health, effectively manage sexual dysfunctions, reduce their frequency, and enhance psychophysical well-being. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Participant Masking: Participants are unaware of the treatment they are receiving. This helps prevent biases in reporting outcomes based on knowledge of the treatment.
Outcomes Assessor Masking: Individuals responsible for assessing the outcomes of the study, such as evaluating patient progress or interpreting test results, are blinded to the treatment group to which participants belong. This prevents biases in outcome assessment. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 113 type: ESTIMATED name: Sexual Nursing care name: Standard Nursing Care measure: Effectiveness of "sexual nursing care" intervention in enhancing sexual awareness measure: psychosocial well-being and relational dynamics of stroke patients and their partners sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Centro Neurolesi Bonino Pulejo status: RECRUITING city: Messina state: Italy/Messina zip: 98124 country: Italy name: Maria Grazia Maggio, PsyD, PhD role: CONTACT phone: +39-09060128840 email: mariagrazia.maggio@irccsme.it name: Maria Grazia Maggio, PsyD, PhD role: PRINCIPAL_INVESTIGATOR lat: 38.19394 lon: 15.55256 hasResults: False
nctId: NCT06278350 id: D2570-201 briefTitle: Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis overallStatus: RECRUITING date: 2024-02-04 date: 2024-12-31 date: 2025-03-31 date: 2024-02-26 date: 2024-02-26 name: InventisBio Co., Ltd class: INDUSTRY briefSummary: This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis . conditions: Plaque Psoriasis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 160 type: ESTIMATED name: D-2570 name: Placebo measure: Percentage of subjects with at least 75% improvement in PASI measure: Percentage of subjects with at least 75% improvement in PASI measure: Percentage of subjects with at least 90% improvement in PASI measure: Percentage of subjects with 100% improvement in PASI measure: Percentage improvement in PASI measure: Percentage of subjects with a PGA measure: The main PK parameters ：Time to maximum measured plasma concentration（Tmax） measure: The main PK parameters ：Peak Plasma Concentration（Cmax) measure: The main PK parameters：Area under the plasma concentration versus time curve（AUC） measure: The main PK parameters：Vz/F (apparent volume of distribution) measure: The main PK parameters： Half-life（t1/2） measure: The main PK parameters： Mean Residence Time (MRT) measure: The main PK parameters：CL/F (apparent clearance) measure: Weight and height will be combined to report BMI in kg/m^2 measure: Incidence and severity of AEs based on NCI CTCAE V5.0 measure: Incidence and severity of TEAEs based on NCI CTCAE V5.0 sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University People's Hospital status: RECRUITING city: Beijing country: China name: Jianzhong Zhang role: CONTACT phone: 13911815813 email: rmzjz@126.com name: Cheng Zhou role: CONTACT phone: 010-88325470 email: zhoucheng@live.cn lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06278337 id: C19-35 briefTitle: X-linked Moesin Associated Immunodeficiency acronym: X-MAIDReg overallStatus: RECRUITING date: 2021-08-12 date: 2026-08-12 date: 2027-01-12 date: 2024-02-26 date: 2024-02-26 name: Institut National de la Santé Et de la Recherche Médicale, France class: OTHER_GOV briefSummary: Moesin deficiency was initially described in 7 male participants aged 4 to 69 years and is characterized by lymphopenia of the 3 lineages and moderate neutropenia. Genetically, 6 out of 7 participants had the same missense mutation in the moesin gene located on the X chromosome. The 7th patient has a mutation leading to the premature introduction of a STOP codon into the protein.Clinically the 7 participants with X-linked moesin-associated immunodeficiency all presented with recurrent bacterial infections of the respiratory, gastrointestinal or urinary tracts, and some had severe varicella.Therapeutically, in the absence of a molecular diagnosis and due to his SCID-like phenotype, one patient was treated with geno-identical hematopoietic stem cell transplantation . The remaining are untreated or treated with immunoglobulin substitution and/or prophylactic antibiotics.
nctId: NCT06278324 id: C1736 id: 2023-A02286-39 type: REGISTRY domain: ANSM briefTitle: Effectiveness of a Nasal Spray on Viral Respiratory Infections overallStatus: RECRUITING date: 2024-01-26 date: 2024-05 date: 2024-07 date: 2024-02-26 date: 2024-02-26 name: CEN Biotech class: INDUSTRY name: Urgo Research, Innovation & Development briefSummary: There is no cure for cold or flu, most people recover in about within two weeks. Paracetamol may be used to reduce aches or treat fever, headache, or body aches. Antiviral solutions ranging from simple universal saline solutions to novel compounds have been proposed to provide a temporary barrier to prevent viral infection and propagation.
This clinical investigation is conducted to assess the performance, clinical benefit and safety of this nasal spray in patients with early symptoms of acute respiratory disease whether or not infection is related to common cold, flu or COVID virus. Indeed, presence of early symptoms of acute respiratory infection does not always imply viral infectionAntigen self-tests are available to confirm viral infection with flu viruses or severe acute respiratory syndrome (SARS-CoV-2). However, influenza and other winter viruses are not systematically searched for in general population, because this is of neither collective nor individual interest. To be as pragmatic as possible, we chose to assess performance and safety of the nasal spray on intended users in real conditions. Patients with early symptoms of cold, flu or COVID, are enrolled regardless their PCR test positivity confirming viral infection at the time of enrollment. For study needs, the primary endpoint, which aims to assess the performance of the nasal spray in terms of stopping the viral infection, is assessed in a subgroup of patients with a positive PCR test with flu, COVID or common cold virus in the nasal sample collected at enrollment. conditions: Acute Respiratory Tract Infection conditions: Flu, Human conditions: COVID-19 conditions: Common Cold studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Trial, parallel arms (1:1 allocation ratio), single center, with a blind assessment for primary outcome primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Blinded assessment of viral load analyses whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Nasal Spray HSV Treatment measure: Performance of nasal spray in eliminating viruses measure: Changes from baseline in viral load measure: Rate of patients cleared from viral infection measure: Rate of patients with improved viral infection measure: Rate of patients with worsening viral infection measure: Rate of patients with new viral infection measure: Changes in symptom severity measure: Duration of illness measure: Time to clinical improvement of the symptoms measure: Adverse event occurence measure: Patient opinion of nasal spray measure: Nasal spray safety sex: ALL minimumAge: 18 Years maximumAge: 84 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cen Experimental status: RECRUITING city: Dijon state: Burgundy zip: 21000 country: France name: Amandine FRY role: CONTACT phone: 0033380680513 email: amandine.fry@groupecen.com name: Carole PERRIN, MD role: PRINCIPAL_INVESTIGATOR lat: 47.31667 lon: 5.01667 hasResults: False
nctId: NCT06278311 id: 20235761 briefTitle: Correlation of Toxins With Gastrointestinal (GI) and Overall Health overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-02 date: 2025-02 date: 2024-02-26 date: 2024-03-28 name: Vibrant America Clinical Lab class: INDUSTRY name: Los Angeles Integrative Gastroenterology and Nutrition, Inc briefSummary: The goal of this observational study is to evaluate the levels of urinary environmental toxins, heavy metals, PFAS and mycotoxins with gastrointestinal (GI) and overall health. conditions: Gastrointestinal Diseases studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 250 type: ESTIMATED measure: Determination of the Total Toxicity score measure: Determination of the Symptom score measure: Determination of the Diagnosis score measure: Determination of individual scores sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Los Angeles Integrative Gastroenterology and Nutrition, Inc city: Los Angeles state: California zip: 90067 country: United States name: Dr. Farshid S Rahbar, MD role: CONTACT phone: 310-289-8000 email: Research@laintegrativegi.com name: Dr. Farshid S Rahbar, MD role: PRINCIPAL_INVESTIGATOR lat: 34.05223 lon: -118.24368 facility: Vibrant America Clinical Lab city: Santa Clara state: California zip: 95054 country: United States name: Hari K Krishnamurthy, MS role: CONTACT phone: 866-364-0963 email: hari@vibrantsci.com name: Hari K Krishnamurthy, MS role: PRINCIPAL_INVESTIGATOR lat: 37.35411 lon: -121.95524 hasResults: False
nctId: NCT06278298 id: REC/012/003318 briefTitle: Different Level of ECSWT in Post Mastectomy Lymphedema overallStatus: ACTIVE_NOT_RECRUITING date: 2023-03-01 date: 2024-06-01 date: 2025-01-01 date: 2024-02-26 date: 2024-02-26 name: Cairo University class: OTHER briefSummary: to investigate the effectiveness of different dosages of ECSW in the treatment of post mastectomy lymphedema volume and quality of life (Qol) conditions: Lymphedema of Upper Limb studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 45 type: ESTIMATED name: Shockwave name: CDT measure: lymphedema volume measure: skin thickness of the arm sex: FEMALE minimumAge: 30 Years maximumAge: 60 Years stdAges: ADULT facility: Cairo University city: Giza state: Dokki zip: 12612 country: Egypt lat: 30.00808 lon: 31.21093 hasResults: False
nctId: NCT06278285 id: 21-AOIP-01 briefTitle: Effect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery acronym: Maigrir_OT overallStatus: RECRUITING date: 2024-03-06 date: 2025-09-01 date: 2026-03-01 date: 2024-02-26 date: 2024-03-18 name: Centre Hospitalier Universitaire de Nice class: OTHER briefSummary: Normalizing weight gain and preventing the redistribution of body fat is a major health issue, and could help prevent the onset of various symptoms of metabolic syndrome. Above all, it is important to understand the mechanisms by which these different treatments affect adipose tissue. To this end, the investigators will first study the impact of GLP-1 analogues on adipose tissue. The main objective is to show that subjects treated with a GLP-1 agonist have a significant change in their oxytocin levels compared with subjects not treated with a GLP-1 agonist. conditions: Obesity studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 40 type: ESTIMATED name: Blood GLP1 name: Blood No treated GLP1 measure: Rate of oxytocin measure: Fibrosis rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Nice - Hôpital de l'Archet status: RECRUITING city: Nice state: Alpes-maritimes zip: 06200 country: France name: Roux Christian, PhD role: CONTACT phone: +33492039220 email: roux.c@chu-nice.fr name: Iannelli Antonio, PhD role: CONTACT phone: +33492035900 email: iannelli.a@chu-nice.fr name: Iannelli Antonio, PhD role: PRINCIPAL_INVESTIGATOR lat: 43.70313 lon: 7.26608 hasResults: False